Form 4: Viridian Therapeutics CEO Stephen Mahoney Reports Stock Option and RSU Grants
SEC Form 4 Filing
Stephen F. Mahoney, CEO of Viridian Therapeutics, reports the acquisition of stock options and restricted stock units (RSUs) on March 3, 2025.
Summary
- On March 3, 2025, Stephen F. Mahoney, the President and CEO of Viridian Therapeutics, acquired stock options and restricted stock units.
- Mahoney acquired options to purchase 440,565 shares of common stock at an exercise price of $14.41.
- These options vest in 48 equal monthly installments starting from the grant date, contingent upon continued service.
- Mahoney also acquired 73,428 restricted stock units (RSUs), each representing a right to receive one share of common stock.
- The RSUs vest over a four-year period, with 25% vesting annually from the grant date, also contingent upon continued service.
Sentiment
Score: 7
Explanation: The document reflects a routine executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive as it indicates continued commitment from the CEO.
Positives
- The grants of stock options and RSUs align the CEO's interests with those of the shareholders, incentivizing long-term value creation.
Risks
- The vesting of the options and RSUs is contingent upon the CEO's continued service, creating a potential risk if the CEO were to leave the company before the vesting is complete.
Industry Context
Stock option and RSU grants are common practices in the biotechnology industry to incentivize and retain key executives. These grants align executive compensation with company performance and shareholder value.
Comparison to Industry Standards
- Stock option grants are a standard component of executive compensation packages in the biotech industry, often benchmarked against peer companies of similar size and stage of development.
- Companies like Amgen, Regeneron, and Biogen also utilize stock options and RSUs as part of their executive compensation plans.
- The vesting schedules (monthly for options, annual for RSUs) are typical for such grants, ensuring long-term commitment from the executive.
Stakeholder Impact
- Shareholders may view the grants positively as they incentivize the CEO to increase shareholder value.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the transaction (grant of stock options and RSUs) |
| 03/03/2025 | Start date for monthly vesting of stock options |
| 03/03/2025 | Start date for annual vesting of RSUs |
| 03/03/2035 | Expiration date of the stock options |
| 03/04/2025 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.